Validating Predictive Models and Biomarkers of Radiotherapy Toxicity to Reduce Side-Effects and Improve Quality of Life in Cancer Survivors

The purpose of this international study is to try to predict which patients are more likely to have side effects from radiotherapy

News

Action Radiotherapy dedicated to improving radiotherapy treatment!

The charity Action Radiotherapy was launched in 2012, having been formed from the ACORRN (The Academic Clinical Oncology and Radiobiology Research Network).

Poster at ESTRO 35 Conference in Turin!

From Friday april 29 to Tuesday 3 may the annual ESTRO-Congress will take place in Turin, Italy. ESTRO, the European SocieTy for Radiotherapy & Oncology, is a non-profit and scientific organisation that fosters the role of Radiation Oncology in order to improve patients’ care in the multimodality treatment of cancer. In the Physics track: (Radio)biological modelling the poster from G. Defraene, W. Van Elmpt and D.

Tim Ward runs Manchester Marathon for Pelvic Radiation Disease Association!

10th April 2016, Manchester, Tim Ward, a member of the REQUITE Patient Advisory Group, finished the Greater Manchester Marathon. Five years ago, April 4th 2011, he was diagnosed with cancer and he  has undergone hormone therapy, radiotherapy and Hyperbaric Oxygen therapy.  He is fit and well although like many cancer patients he still suffers from the late effects of the treatment.

REQUITE on twitter!

You can follow the REQUITE project on twitter @RequiteProject

 

Older news

Recruitment

Breast
1672
Lung
353
Prostate
1481

Events

4rd Annual REQUITE meeting and 8th Annual Radiogenomics Consortium meeting

Dates: 
Monday, 11 July, 2016 to Wednesday, 13 July, 2016
Location: 
Hotel NH Maastricht 6229GV Maastricht
Netherlands
NL